Gimv NV is one of the leading investment companies in Belgium. At the end of March 2024, the portfolio had an estimated market value of EUR 1,623.3 million broken down by type of shares as follows: - investments in unlisted companies (98.9%); - investments in listed companies (1.1%). Portfolio breaks down geographically by value as follows: Belgium (35.6%), Germany (18.7%), the Netherlands (18.6%), France (18.4%) and Rest of the World (7.7%).

Employees

Sector

Investment Management & Fund Operators

Calendar

02-19 - Q4 2026 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
14/01/26	45.05 €	-0.44%	20,141
13/01/26	45.25 €	-1.09%	21,732
12/01/26	45.75 €	0.00%	18,270
09/01/26	45.75 €	+1.55%	17,009
08/01/26	45.05 €	+0.22%	14,830

Real-time Euronext Bruxelles, January 14, 2026 at 04:55 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

45.05EUR

Average target price

50.33EUR

Spread / Average Target

+11.73%

Consensus

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 14/01/2026 GMT			5-day change	1st Jan Change
45.05 ^EUR	-0.44%		+0.90%	+0.90%

01-09	Kinaset Therapeutics, Inc. announced that it has received $103 million in funding from a group of investors	CI
01-07	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors	CI

Capitalization	1.66B 1.93B 1.54B 1.44B 2.68B 174B 2.89B 17.75B 6.98B 83.46B 7.25B 7.1B 306B	P/E ratio 2024 *	-	P/E ratio 2025	-
Enterprise value	1.66B 1.93B 1.54B 1.44B 2.68B 174B 2.89B 17.75B 6.98B 83.46B 7.25B 7.1B 306B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	58.13%	Yield 2024	5.84%	Yield 2025	6.6%

01-09	Kinaset Therapeutics, Inc. announced that it has received $103 million in funding from a group of investors	CI
01-07	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors	CI
12-16	Ipsen Closes ImCheck Therapeutics Purchase	MT
12-15	Ipsen S.A. completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV and others.	CI
12-09	Mediar Therapeutics, Inc. announced that it expects to receive $75.69963 million in funding	CI
11-28	Tinc, Infravest Invest EUR100 Million in Parking Solutions Company Interparking	MT
11-28	TINC announces an investment in Interparking	RE
11-27	Gimv joins forces with CNP to accelerate global expansion of Equine Care Group	RE
11-27	Gimv to Buy Minority Stake in Animal Healthcare Company Equine Care	MT
11-26	Gimv NV signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA.	CI
11-20	Gimv NV Reports Earnings Results for the Half Year Ended September 30, 2025	CI
11-20	Gimv posts H1 net profit of EUR 126.9 mln	RE
11-05	Quality Guard Nv announced that it has received funding from Gimv NV	CI

01-12	Gimv : Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors	PU
01-12	EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases	AQ
01-12	Gimv : Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases	PU
01-08	Gimv : Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD	PU
01-07	Gimv : Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio	PU

Gimv NV Share Price

Equities

GIMB

BE0003699130

Investment Management & Fund Operators

Valuation: Gimv NV

Chart: Gimv NV

Latest news: Gimv NV

Press Releases: Gimv NV

News in other languages: Gimv NV

Quotes and Performance

Course Extremes

Managers and Directors: Gimv NV

Investment Management

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

12-05	Gimv : Cegeka versterkt Raad van Bestuur om groei en internationalisering te versnellen
12-02	Gimv : Biotalys krijgt goedkeuring van Amerikaanse EPA voor EVOCA
12-01	Analistenrapporten domineren koersbewegingen in Bel20
11-28	TINC investeert samen met Infravest in Interparking
11-27	Gimv prend une participation minoritaire dans le groupe de santé équine ECG

1 day	-0.44%
1 week	+0.90%
Current month	+0.90%
1 month	+3.33%
3 months	-3.01%
6 months	+8.29%
Current year	+0.90%

1 week	44.65	46.05
1 month	43.3	46.05
Current year	43.85	46.05
1 year	34.5	48.15
3 years	34.5	48.15
5 years	34.5	58
10 years	34.5	59.4

Manager	Title	Age	Since
Koen Dejonckheere CEO	Chief Executive Officer	57	31/12/2007
Kristof Vande Capelle DFI	Director of Finance/CFO	57	31/08/2007
Johan Creemers CTO	Chief Tech/Sci/R&D Officer	-	30/11/2021

Director	Title	Age	Since
Koen Dejonckheere BRD	Director/Board Member	57	31/12/2007
Luc Missorten BRD	Director/Board Member	71	24/06/2014
Manon Janssen BRD	Director/Board Member	65	31/12/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GIMV NV	-0.44%	+0.90%	+13.91%	-0.66%	1.94B
BLACKSTONE INC.	+2.23%	-2.42%	-4.26%	+86.63%	122B
KKR & CO. INC.	+1.54%	-2.75%	-6.49%	+144.59%	116B
ARES MANAGEMENT CORPORATION	+0.42%	-3.45%	-3.17%	+119.34%	37.28B
THE CARLYLE GROUP INC.	+0.11%	-0.14%	+29.72%	+95.53%	23.6B
AMUNDI	+0.14%	+2.08%	+20.41%	+22.31%	17.39B
ARES CAPITAL CORPORATION	+1.95%	+1.41%	-5.52%	+10.48%	14.66B
FRANKLIN RESOURCES, INC.	+1.38%	+2.03%	+34.97%	-14.77%	13.18B
HDFC ASSET MANAGEMENT COMPANY LIMITED	+2.75%	-2.59%	+33.22%	+137.30%	11.79B
BLUE OWL CAPITAL INC.	+1.96%	-2.74%	-30.23%	+26.01%	10.17B
Average	+1.20%	+1.01%	+8.25%	+62.68%	36.75B
Weighted average by Cap.	+1.55%	+1.72%	+0.43%	+98.58%

	2024	2025
Net sales	292M 340M 272M 253M 472M 30.72B 509M 3.13B 1.23B 14.69B 1.28B 1.25B 53.84B	301M 351M 280M 261M 487M 31.66B 525M 3.22B 1.27B 15.14B 1.32B 1.29B 55.49B
Net income	217M 253M 202M 188M 351M 22.84B 378M 2.32B 914M 10.93B 949M 929M 40.04B	219M 255M 204M 190M 354M 23.04B 382M 2.34B 922M 11.02B 957M 937M 40.39B
Net Debt	-	-